Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

about

Design considerations for early-phase clinical trials of immune-oncology agents

P2860

Q56334001-856E9461-6A29-496C-B5AF-06AFB5566FF5

P2860

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Item

http://www.wikidata.org/entity/Q53522981

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

@en

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

@nl

type

Item

label

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

@en

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

@nl

prefLabel

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

@en

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

@nl

P1476

Dose-finding designs for trials of molecularly targeted agents and immunotherapies

@en

P2093

Anastasia Ivanova

http://www.w3.org/2001/XMLSchema#string

Gary K Schwartz

http://www.w3.org/2001/XMLSchema#string

Gulam A Manji

http://www.w3.org/2001/XMLSchema#string

Jimmy K Duong

http://www.w3.org/2001/XMLSchema#string

Jonathan Shtaynberger

http://www.w3.org/2001/XMLSchema#string

Shing M Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Clinical trial designs for cytostatic agents: are new approaches needed?

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans

Inducible apoptosis as a safety switch for adoptive cell therapy

Phase I/II adaptive design for drug combination oncology trials

Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.

Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.

P304

477-494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10543406.2017.1289952

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cody Chiuzan

P577

2017-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28166468

http://www.w3.org/2001/XMLSchema#string

P932

5383533

http://www.w3.org/2001/XMLSchema#string

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

about

P2860

P2860

Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932